Akademska digitalna zbirka SLovenije - logo
E-viri
Recenzirano Odprti dostop
  • A novel liposomal adjuvant ...
    van Dissel, Jaap T; Joosten, Simone A; Hoff, Søren T; Soonawala, Darius; Prins, Corine; Hokey, David A; O’Dee, Dawn M; Graves, Andrew; Thierry-Carstensen, Birgit; Andreasen, Lars V; Ruhwald, Morten; de Visser, Adriëtte W; Agger, Else Marie; Ottenhoff, Tom H.M; Kromann, Ingrid; Andersen, Peter

    Vaccine, 12/2014, Letnik: 32, Številka: 52
    Journal Article

    Highlights • Novel liposome based adjuvant formulation CAF01 safe in first-in-human clinical trial. • H1 antigen + CAF01 adjuvant induce T-cell responses in human. • T-cell immunity is very long-lasting, specific responses detectable up to 150 weeks.